Genome Web Breaking News
- In Brief This Week: Illumina, Natera, Sherlock Biosciences, and More
- FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE
- NCI Awards InheRET $2M SBTT Grant to Improve Inherited Disease Detection
- CRISPR-Chip Maker Cardea Bio Raises $7.5M in First Close of Series A2 Financing Round
- Qiagen Acquires Remaining Stake in NeuMoDx Molecular for $248M
Stat
- STAT Plus: Up and down the ladder: The latest comings and goings
- STAT Plus: Pharmalittle: Roche says its drug helped Covid-19 patients; Trump expected to finalize drug importation plan
- Opinion: Three lessons from Covid-19 on accelerating biopharma innovation
- Opinion: How the CDC and others are failing Black women during childbirth
- An expert’s take on what the U.S., U.K did wrong in Covid-19 communications — and what others did right
Xconomy news
- Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
- Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
- BIO Chief: “Reckless” Executive Order on Drug Prices Threatens Innovation
- Finch Therapeutics Fetches $90M to Advance Microbiome Drug Pipeline
- Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug
Fierce Biotech
- Under pressure, Pfizer, Moderna (and soon AstraZeneca) publish COVID-19 vaccine protocols
- Roden, fresh from BMS-Celgene merger, lands VC role at MPM
- Brii hires Gilead's China general manager Luo to drive expansion
- ESMO: Alkermes' major I-O hope sees progress across early cancer tests
- ESMO: Merck chalks one up for TIGIT with phase 1 Keytruda combo
Fierce Medical Devices
- Cellex, Gauss aim for smartphone-powered coronavirus test, offering rapid results at home
- Illumina in talks to reacquire its cancer blood test spinout, Grail: Bloomberg
- FDA ranks the performance of 58 molecular coronavirus tests from major developers
- Defining COVID-19 immunity: CDC, EU researchers tap Siemens Healthineers to help standardize antibody tests
- Regenerative tissue developer Aziyo Biologics files for $58M IPO